nodes	percent_of_prediction	percent_of_DWPC	metapath
Vidarabine—DPP4—Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)—CDX2—colon cancer	0.0397	0.193	CbGpPWpGaD
Vidarabine—DPP4—Incretin synthesis, secretion, and inactivation—CDX2—colon cancer	0.0353	0.171	CbGpPWpGaD
Vidarabine—DPP4—blood vessel—colon cancer	0.0323	0.0926	CbGeAlD
Vidarabine—Ear discomfort—Capecitabine—colon cancer	0.0225	0.0524	CcSEcCtD
Vidarabine—DPP4—embryo—colon cancer	0.0193	0.0552	CbGeAlD
Vidarabine—ADA—renal system—colon cancer	0.0184	0.0528	CbGeAlD
Vidarabine—DPP4—epithelium—colon cancer	0.0157	0.0451	CbGeAlD
Vidarabine—ADK—smooth muscle tissue—colon cancer	0.0156	0.0448	CbGeAlD
Vidarabine—ADA—lymphoid tissue—colon cancer	0.0153	0.0438	CbGeAlD
Vidarabine—DPP4—smooth muscle tissue—colon cancer	0.0152	0.0434	CbGeAlD
Vidarabine—ADA—digestive system—colon cancer	0.0151	0.0433	CbGeAlD
Vidarabine—ADK—renal system—colon cancer	0.0151	0.0431	CbGeAlD
Vidarabine—DPP4—renal system—colon cancer	0.0146	0.0418	CbGeAlD
Vidarabine—Coronary artery disease—Vincristine—colon cancer	0.0143	0.0334	CcSEcCtD
Vidarabine—ADA—bone marrow—colon cancer	0.0139	0.0399	CbGeAlD
Vidarabine—ADORA2A—lymphoid tissue—colon cancer	0.0139	0.0399	CbGeAlD
Vidarabine—ADA—vagina—colon cancer	0.0133	0.0382	CbGeAlD
Vidarabine—ADK—lymphoid tissue—colon cancer	0.0125	0.0358	CbGeAlD
Vidarabine—DPP4—lymphoid tissue—colon cancer	0.0121	0.0347	CbGeAlD
Vidarabine—DPP4—digestive system—colon cancer	0.012	0.0343	CbGeAlD
Vidarabine—DPP4—Peptide hormone metabolism—CDX2—colon cancer	0.012	0.0581	CbGpPWpGaD
Vidarabine—ADK—bone marrow—colon cancer	0.0114	0.0326	CbGeAlD
Vidarabine—DPP4—bone marrow—colon cancer	0.011	0.0316	CbGeAlD
Vidarabine—ADK—vagina—colon cancer	0.0109	0.0312	CbGeAlD
Vidarabine—DPP4—vagina—colon cancer	0.0106	0.0303	CbGeAlD
Vidarabine—ADORA2A—liver—colon cancer	0.0102	0.0293	CbGeAlD
Vidarabine—ADK—liver—colon cancer	0.0092	0.0263	CbGeAlD
Vidarabine—Sinus tachycardia—Capecitabine—colon cancer	0.00915	0.0214	CcSEcCtD
Vidarabine—DPP4—liver—colon cancer	0.00892	0.0255	CbGeAlD
Vidarabine—ADA—lymph node—colon cancer	0.00863	0.0247	CbGeAlD
Vidarabine—Taste metallic—Methotrexate—colon cancer	0.00863	0.0201	CcSEcCtD
Vidarabine—DPP4—Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)—CTNNB1—colon cancer	0.00781	0.0379	CbGpPWpGaD
Vidarabine—Adenosine triphosphate—AKT1—colon cancer	0.00756	0.463	CrCbGaD
Vidarabine—Adenosine monophosphate—SRC—colon cancer	0.00745	0.456	CrCbGaD
Vidarabine—ADK—lymph node—colon cancer	0.00705	0.0202	CbGeAlD
Vidarabine—DPP4—Incretin synthesis, secretion, and inactivation—CTNNB1—colon cancer	0.00695	0.0337	CbGpPWpGaD
Vidarabine—Myocardial ischaemia—Irinotecan—colon cancer	0.00685	0.016	CcSEcCtD
Vidarabine—DPP4—lymph node—colon cancer	0.00684	0.0196	CbGeAlD
Vidarabine—Numbness—Vincristine—colon cancer	0.00682	0.0159	CcSEcCtD
Vidarabine—Myocardial ischaemia—Fluorouracil—colon cancer	0.00656	0.0153	CcSEcCtD
Vidarabine—Tingling sensation—Fluorouracil—colon cancer	0.00656	0.0153	CcSEcCtD
Vidarabine—Sensory loss—Vincristine—colon cancer	0.00653	0.0152	CcSEcCtD
Vidarabine—Numbness—Fluorouracil—colon cancer	0.00636	0.0148	CcSEcCtD
Vidarabine—ADK—Nucleotide metabolism—TYMS—colon cancer	0.00621	0.0301	CbGpPWpGaD
Vidarabine—Sensory loss—Fluorouracil—colon cancer	0.00609	0.0142	CcSEcCtD
Vidarabine—Respiratory failure—Vincristine—colon cancer	0.00576	0.0134	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—TOP1—colon cancer	0.00562	0.0273	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—BAX—colon cancer	0.00546	0.0265	CbGpPWpGaD
Vidarabine—Torsade de pointes—Capecitabine—colon cancer	0.00525	0.0123	CcSEcCtD
Vidarabine—Ventricular fibrillation—Capecitabine—colon cancer	0.00481	0.0112	CcSEcCtD
Vidarabine—Tingling sensation—Capecitabine—colon cancer	0.00458	0.0107	CcSEcCtD
Vidarabine—Myocardial ischaemia—Capecitabine—colon cancer	0.00458	0.0107	CcSEcCtD
Vidarabine—Extrasystoles—Capecitabine—colon cancer	0.00438	0.0102	CcSEcCtD
Vidarabine—ADA—Nucleotide metabolism—TYMS—colon cancer	0.00422	0.0205	CbGpPWpGaD
Vidarabine—Chest discomfort—Capecitabine—colon cancer	0.00416	0.00972	CcSEcCtD
Vidarabine—Ventricular extrasystoles—Capecitabine—colon cancer	0.00408	0.00952	CcSEcCtD
Vidarabine—Cerebrovascular accident—Irinotecan—colon cancer	0.00408	0.00952	CcSEcCtD
Vidarabine—ADA—p73 transcription factor network—BAX—colon cancer	0.00402	0.0195	CbGpPWpGaD
Vidarabine—Burning sensation—Methotrexate—colon cancer	0.00395	0.00922	CcSEcCtD
Vidarabine—Cardiac failure—Fluorouracil—colon cancer	0.00392	0.00916	CcSEcCtD
Vidarabine—Cardiac arrest—Vincristine—colon cancer	0.0039	0.00911	CcSEcCtD
Vidarabine—Cardiac arrest—Irinotecan—colon cancer	0.0038	0.00887	CcSEcCtD
Vidarabine—Blood pressure increased—Capecitabine—colon cancer	0.00369	0.0086	CcSEcCtD
Vidarabine—Injection site reaction—Capecitabine—colon cancer	0.00366	0.00855	CcSEcCtD
Vidarabine—Cardiac arrest—Fluorouracil—colon cancer	0.00364	0.0085	CcSEcCtD
Vidarabine—ADK—Metabolism—CA7—colon cancer	0.00359	0.0174	CbGpPWpGaD
Vidarabine—Apnoea—Methotrexate—colon cancer	0.00324	0.00755	CcSEcCtD
Vidarabine—ADORA2A—Circadian rythm related genes—TOP1—colon cancer	0.00323	0.0157	CbGpPWpGaD
Vidarabine—Acute coronary syndrome—Vincristine—colon cancer	0.00312	0.00728	CcSEcCtD
Vidarabine—Myocardial infarction—Vincristine—colon cancer	0.0031	0.00724	CcSEcCtD
Vidarabine—Acute coronary syndrome—Irinotecan—colon cancer	0.00304	0.00709	CcSEcCtD
Vidarabine—Sweating—Vincristine—colon cancer	0.00303	0.00708	CcSEcCtD
Vidarabine—Myocardial infarction—Irinotecan—colon cancer	0.00302	0.00705	CcSEcCtD
Vidarabine—Sweating—Irinotecan—colon cancer	0.00295	0.00689	CcSEcCtD
Vidarabine—Acute coronary syndrome—Fluorouracil—colon cancer	0.00291	0.00679	CcSEcCtD
Vidarabine—Myocardial infarction—Fluorouracil—colon cancer	0.00289	0.00675	CcSEcCtD
Vidarabine—Hypoaesthesia—Vincristine—colon cancer	0.00282	0.00659	CcSEcCtD
Vidarabine—Atrial fibrillation—Capecitabine—colon cancer	0.00282	0.00659	CcSEcCtD
Vidarabine—Bradycardia—Irinotecan—colon cancer	0.00281	0.00657	CcSEcCtD
Vidarabine—Respiratory failure—Methotrexate—colon cancer	0.00279	0.00652	CcSEcCtD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—CDKN1A—colon cancer	0.00276	0.0134	CbGpPWpGaD
Vidarabine—Cardiac failure—Capecitabine—colon cancer	0.00274	0.0064	CcSEcCtD
Vidarabine—Cerebrovascular accident—Capecitabine—colon cancer	0.00273	0.00637	CcSEcCtD
Vidarabine—Cardiac disorder—Vincristine—colon cancer	0.00263	0.00615	CcSEcCtD
Vidarabine—Hypoaesthesia—Fluorouracil—colon cancer	0.00263	0.00615	CcSEcCtD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—EP300—colon cancer	0.00263	0.0127	CbGpPWpGaD
Vidarabine—Flushing—Irinotecan—colon cancer	0.00257	0.00599	CcSEcCtD
Vidarabine—Cardiac disorder—Irinotecan—colon cancer	0.00257	0.00599	CcSEcCtD
Vidarabine—Mediastinal disorder—Vincristine—colon cancer	0.00256	0.00597	CcSEcCtD
Vidarabine—Cardiac arrest—Capecitabine—colon cancer	0.00254	0.00594	CcSEcCtD
Vidarabine—Mood swings—Capecitabine—colon cancer	0.00253	0.00592	CcSEcCtD
Vidarabine—Mediastinal disorder—Irinotecan—colon cancer	0.00249	0.00582	CcSEcCtD
Vidarabine—Arrhythmia—Irinotecan—colon cancer	0.00247	0.00577	CcSEcCtD
Vidarabine—ADA—Metabolism—CA7—colon cancer	0.00244	0.0118	CbGpPWpGaD
Vidarabine—Back pain—Vincristine—colon cancer	0.00239	0.00558	CcSEcCtD
Vidarabine—Arrhythmia—Fluorouracil—colon cancer	0.00237	0.00552	CcSEcCtD
Vidarabine—DPP4—Peptide hormone metabolism—CTNNB1—colon cancer	0.00236	0.0114	CbGpPWpGaD
Vidarabine—Back pain—Irinotecan—colon cancer	0.00233	0.00543	CcSEcCtD
Vidarabine—Bronchospasm—Capecitabine—colon cancer	0.00227	0.00531	CcSEcCtD
Vidarabine—Agitation—Vincristine—colon cancer	0.00227	0.0053	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—CDX2—colon cancer	0.00226	0.011	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—PTGS2—colon cancer	0.00222	0.0108	CbGpPWpGaD
Vidarabine—Abdominal discomfort—Capecitabine—colon cancer	0.00222	0.00517	CcSEcCtD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—EP300—colon cancer	0.00218	0.0106	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CHST5—colon cancer	0.00217	0.0106	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ODC1—colon cancer	0.00217	0.0106	CbGpPWpGaD
Vidarabine—Vision blurred—Fluorouracil—colon cancer	0.00217	0.00507	CcSEcCtD
Vidarabine—Syncope—Irinotecan—colon cancer	0.00216	0.00504	CcSEcCtD
Vidarabine—Convulsion—Vincristine—colon cancer	0.00214	0.005	CcSEcCtD
Vidarabine—Hypertension—Vincristine—colon cancer	0.00213	0.00498	CcSEcCtD
Vidarabine—Loss of consciousness—Irinotecan—colon cancer	0.00212	0.00494	CcSEcCtD
Vidarabine—Cough—Irinotecan—colon cancer	0.0021	0.0049	CcSEcCtD
Vidarabine—Hypertension—Irinotecan—colon cancer	0.00208	0.00485	CcSEcCtD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—VEGFA—colon cancer	0.00207	0.01	CbGpPWpGaD
Vidarabine—ADA—p73 transcription factor network—CDKN1A—colon cancer	0.00204	0.00988	CbGpPWpGaD
Vidarabine—Acute coronary syndrome—Capecitabine—colon cancer	0.00203	0.00474	CcSEcCtD
Vidarabine—Cerebrovascular accident—Methotrexate—colon cancer	0.00203	0.00474	CcSEcCtD
Vidarabine—Discomfort—Irinotecan—colon cancer	0.00202	0.00473	CcSEcCtD
Vidarabine—Myocardial infarction—Capecitabine—colon cancer	0.00202	0.00472	CcSEcCtD
Vidarabine—Anaphylactic shock—Vincristine—colon cancer	0.00202	0.00471	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—CCND1—colon cancer	0.002	0.00972	CbGpPWpGaD
Vidarabine—Convulsion—Fluorouracil—colon cancer	0.002	0.00466	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—TYMS—colon cancer	0.00198	0.00961	CbGpPWpGaD
Vidarabine—Anaphylactic shock—Irinotecan—colon cancer	0.00196	0.00459	CcSEcCtD
Vidarabine—Chest pain—Fluorouracil—colon cancer	0.00196	0.00458	CcSEcCtD
Vidarabine—Hyperhidrosis—Vincristine—colon cancer	0.00195	0.00455	CcSEcCtD
Vidarabine—Discomfort—Fluorouracil—colon cancer	0.00194	0.00453	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—CDKN1A—colon cancer	0.00194	0.00941	CbGpPWpGaD
Vidarabine—ADA—p73 transcription factor network—EP300—colon cancer	0.00194	0.0094	CbGpPWpGaD
Vidarabine—Shock—Irinotecan—colon cancer	0.00193	0.00451	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—MUC2—colon cancer	0.00192	0.00932	CbGpPWpGaD
Vidarabine—Hyperhidrosis—Irinotecan—colon cancer	0.0019	0.00443	CcSEcCtD
Vidarabine—Mood swings—Methotrexate—colon cancer	0.00189	0.0044	CcSEcCtD
Vidarabine—Hypotension—Vincristine—colon cancer	0.00188	0.0044	CcSEcCtD
Vidarabine—Bradycardia—Capecitabine—colon cancer	0.00188	0.0044	CcSEcCtD
Vidarabine—Anaphylactic shock—Fluorouracil—colon cancer	0.00188	0.00439	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—EP300—colon cancer	0.00184	0.00895	CbGpPWpGaD
Vidarabine—Hypoaesthesia—Capecitabine—colon cancer	0.00184	0.0043	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Vincristine—colon cancer	0.00184	0.00429	CcSEcCtD
Vidarabine—Tachycardia—Fluorouracil—colon cancer	0.00184	0.00429	CcSEcCtD
Vidarabine—Hypotension—Irinotecan—colon cancer	0.00184	0.00428	CcSEcCtD
Vidarabine—Paraesthesia—Vincristine—colon cancer	0.00181	0.00423	CcSEcCtD
Vidarabine—Paraesthesia—Irinotecan—colon cancer	0.00176	0.00412	CcSEcCtD
Vidarabine—Hypotension—Fluorouracil—colon cancer	0.00176	0.0041	CcSEcCtD
Vidarabine—Dyspnoea—Irinotecan—colon cancer	0.00175	0.00409	CcSEcCtD
Vidarabine—Somnolence—Irinotecan—colon cancer	0.00175	0.00408	CcSEcCtD
Vidarabine—Tinnitus—Capecitabine—colon cancer	0.00173	0.00403	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—NRAS—colon cancer	0.00172	0.00837	CbGpPWpGaD
Vidarabine—Pain—Vincristine—colon cancer	0.00172	0.00403	CcSEcCtD
Vidarabine—Flushing—Capecitabine—colon cancer	0.00172	0.00401	CcSEcCtD
Vidarabine—Cardiac disorder—Capecitabine—colon cancer	0.00172	0.00401	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.00171	0.004	CcSEcCtD
Vidarabine—Paraesthesia—Fluorouracil—colon cancer	0.00169	0.00394	CcSEcCtD
Vidarabine—ADA—p73 transcription factor network—MYC—colon cancer	0.00169	0.00819	CbGpPWpGaD
Vidarabine—Pain—Irinotecan—colon cancer	0.00168	0.00392	CcSEcCtD
Vidarabine—Dyspnoea—Fluorouracil—colon cancer	0.00168	0.00392	CcSEcCtD
Vidarabine—Somnolence—Fluorouracil—colon cancer	0.00167	0.0039	CcSEcCtD
Vidarabine—Mediastinal disorder—Capecitabine—colon cancer	0.00167	0.00389	CcSEcCtD
Vidarabine—Arrhythmia—Capecitabine—colon cancer	0.00165	0.00386	CcSEcCtD
Vidarabine—Abdominal discomfort—Methotrexate—colon cancer	0.00165	0.00385	CcSEcCtD
Vidarabine—Pain—Fluorouracil—colon cancer	0.00161	0.00376	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—MYC—colon cancer	0.00161	0.0078	CbGpPWpGaD
Vidarabine—Dysgeusia—Capecitabine—colon cancer	0.00158	0.00368	CcSEcCtD
Vidarabine—Back pain—Capecitabine—colon cancer	0.00156	0.00364	CcSEcCtD
Vidarabine—Drowsiness—Methotrexate—colon cancer	0.00153	0.00358	CcSEcCtD
Vidarabine—Vision blurred—Capecitabine—colon cancer	0.00152	0.00354	CcSEcCtD
Vidarabine—Tremor—Capecitabine—colon cancer	0.00151	0.00352	CcSEcCtD
Vidarabine—Urticaria—Fluorouracil—colon cancer	0.00149	0.00349	CcSEcCtD
Vidarabine—Hypersensitivity—Vincristine—colon cancer	0.00149	0.00347	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—KRAS—colon cancer	0.00148	0.00721	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ODC1—colon cancer	0.00148	0.00717	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CHST5—colon cancer	0.00148	0.00717	CbGpPWpGaD
Vidarabine—Sweating—Methotrexate—colon cancer	0.00147	0.00343	CcSEcCtD
Vidarabine—Hypersensitivity—Irinotecan—colon cancer	0.00145	0.00338	CcSEcCtD
Vidarabine—Asthenia—Vincristine—colon cancer	0.00145	0.00338	CcSEcCtD
Vidarabine—Syncope—Capecitabine—colon cancer	0.00144	0.00337	CcSEcCtD
Vidarabine—Palpitations—Capecitabine—colon cancer	0.00142	0.00332	CcSEcCtD
Vidarabine—Loss of consciousness—Capecitabine—colon cancer	0.00142	0.00331	CcSEcCtD
Vidarabine—Asthenia—Irinotecan—colon cancer	0.00141	0.00329	CcSEcCtD
Vidarabine—Cough—Capecitabine—colon cancer	0.00141	0.00328	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—PPARG—colon cancer	0.0014	0.00681	CbGpPWpGaD
Vidarabine—Hypertension—Capecitabine—colon cancer	0.00139	0.00325	CcSEcCtD
Vidarabine—Hypersensitivity—Fluorouracil—colon cancer	0.00139	0.00324	CcSEcCtD
Vidarabine—Chest pain—Capecitabine—colon cancer	0.00137	0.0032	CcSEcCtD
Vidarabine—Anxiety—Capecitabine—colon cancer	0.00137	0.00319	CcSEcCtD
Vidarabine—Discomfort—Capecitabine—colon cancer	0.00135	0.00316	CcSEcCtD
Vidarabine—Dry mouth—Capecitabine—colon cancer	0.00134	0.00313	CcSEcCtD
Vidarabine—Dizziness—Vincristine—colon cancer	0.00133	0.00311	CcSEcCtD
Vidarabine—Adenosine triphosphate—ABCB1—colon cancer	0.00132	0.0808	CrCbGaD
Vidarabine—Dizziness—Irinotecan—colon cancer	0.0013	0.00303	CcSEcCtD
Vidarabine—Shock—Capecitabine—colon cancer	0.00129	0.00302	CcSEcCtD
Vidarabine—Tinnitus—Methotrexate—colon cancer	0.00128	0.003	CcSEcCtD
Vidarabine—Tachycardia—Capecitabine—colon cancer	0.00128	0.003	CcSEcCtD
Vidarabine—Vomiting—Vincristine—colon cancer	0.00128	0.00299	CcSEcCtD
Vidarabine—Cardiac disorder—Methotrexate—colon cancer	0.00128	0.00298	CcSEcCtD
Vidarabine—Rash—Vincristine—colon cancer	0.00127	0.00297	CcSEcCtD
Vidarabine—Hyperhidrosis—Capecitabine—colon cancer	0.00127	0.00297	CcSEcCtD
Vidarabine—Dermatitis—Vincristine—colon cancer	0.00127	0.00297	CcSEcCtD
Vidarabine—Headache—Vincristine—colon cancer	0.00126	0.00295	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—HRAS—colon cancer	0.00126	0.00612	CbGpPWpGaD
Vidarabine—Vomiting—Irinotecan—colon cancer	0.00125	0.00292	CcSEcCtD
Vidarabine—Dizziness—Fluorouracil—colon cancer	0.00124	0.0029	CcSEcCtD
Vidarabine—Mediastinal disorder—Methotrexate—colon cancer	0.00124	0.0029	CcSEcCtD
Vidarabine—Rash—Irinotecan—colon cancer	0.00124	0.00289	CcSEcCtD
Vidarabine—Dermatitis—Irinotecan—colon cancer	0.00124	0.00289	CcSEcCtD
Vidarabine—Headache—Irinotecan—colon cancer	0.00123	0.00287	CcSEcCtD
Vidarabine—Hypotension—Capecitabine—colon cancer	0.00123	0.00287	CcSEcCtD
Vidarabine—Nausea—Vincristine—colon cancer	0.0012	0.0028	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Capecitabine—colon cancer	0.0012	0.0028	CcSEcCtD
Vidarabine—Vomiting—Fluorouracil—colon cancer	0.0012	0.00279	CcSEcCtD
Vidarabine—Rash—Fluorouracil—colon cancer	0.00119	0.00277	CcSEcCtD
Vidarabine—Dermatitis—Fluorouracil—colon cancer	0.00119	0.00277	CcSEcCtD
Vidarabine—Paraesthesia—Capecitabine—colon cancer	0.00118	0.00276	CcSEcCtD
Vidarabine—Headache—Fluorouracil—colon cancer	0.00118	0.00275	CcSEcCtD
Vidarabine—Dysgeusia—Methotrexate—colon cancer	0.00117	0.00274	CcSEcCtD
Vidarabine—Dyspnoea—Capecitabine—colon cancer	0.00117	0.00274	CcSEcCtD
Vidarabine—Nausea—Irinotecan—colon cancer	0.00117	0.00272	CcSEcCtD
Vidarabine—Back pain—Methotrexate—colon cancer	0.00116	0.00271	CcSEcCtD
Vidarabine—ADORA2A—Circadian rythm related genes—TYMS—colon cancer	0.00114	0.00552	CbGpPWpGaD
Vidarabine—Vision blurred—Methotrexate—colon cancer	0.00113	0.00264	CcSEcCtD
Vidarabine—Pain—Capecitabine—colon cancer	0.00112	0.00262	CcSEcCtD
Vidarabine—Nausea—Fluorouracil—colon cancer	0.00112	0.00261	CcSEcCtD
Vidarabine—Cough—Methotrexate—colon cancer	0.00105	0.00244	CcSEcCtD
Vidarabine—Urticaria—Capecitabine—colon cancer	0.00104	0.00244	CcSEcCtD
Vidarabine—Convulsion—Methotrexate—colon cancer	0.00104	0.00243	CcSEcCtD
Vidarabine—Chest pain—Methotrexate—colon cancer	0.00102	0.00238	CcSEcCtD
Vidarabine—Discomfort—Methotrexate—colon cancer	0.00101	0.00235	CcSEcCtD
Vidarabine—Anaphylactic shock—Methotrexate—colon cancer	0.000979	0.00228	CcSEcCtD
Vidarabine—Hypersensitivity—Capecitabine—colon cancer	0.000969	0.00226	CcSEcCtD
Vidarabine—Hyperhidrosis—Methotrexate—colon cancer	0.000946	0.00221	CcSEcCtD
Vidarabine—Asthenia—Capecitabine—colon cancer	0.000943	0.0022	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—EP300—colon cancer	0.000917	0.00445	CbGpPWpGaD
Vidarabine—Hypotension—Methotrexate—colon cancer	0.000915	0.00213	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000892	0.00208	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—FGFR3—colon cancer	0.000891	0.00433	CbGpPWpGaD
Vidarabine—Paraesthesia—Methotrexate—colon cancer	0.000879	0.00205	CcSEcCtD
Vidarabine—Dyspnoea—Methotrexate—colon cancer	0.000873	0.00204	CcSEcCtD
Vidarabine—Somnolence—Methotrexate—colon cancer	0.00087	0.00203	CcSEcCtD
Vidarabine—Dizziness—Capecitabine—colon cancer	0.000869	0.00203	CcSEcCtD
Vidarabine—Pain—Methotrexate—colon cancer	0.000837	0.00195	CcSEcCtD
Vidarabine—Vomiting—Capecitabine—colon cancer	0.000836	0.00195	CcSEcCtD
Vidarabine—Rash—Capecitabine—colon cancer	0.000829	0.00194	CcSEcCtD
Vidarabine—Dermatitis—Capecitabine—colon cancer	0.000828	0.00193	CcSEcCtD
Vidarabine—Headache—Capecitabine—colon cancer	0.000824	0.00192	CcSEcCtD
Vidarabine—ADORA2A—Circadian rythm related genes—PPARG—colon cancer	0.000805	0.00391	CbGpPWpGaD
Vidarabine—Nausea—Capecitabine—colon cancer	0.000781	0.00182	CcSEcCtD
Vidarabine—Urticaria—Methotrexate—colon cancer	0.000777	0.00182	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—BRAF—colon cancer	0.000769	0.00373	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—DLC1—colon cancer	0.000755	0.00366	CbGpPWpGaD
Vidarabine—Hypersensitivity—Methotrexate—colon cancer	0.000721	0.00168	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—LGR5—colon cancer	0.00071	0.00344	CbGpPWpGaD
Vidarabine—Asthenia—Methotrexate—colon cancer	0.000702	0.00164	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—FGFR3—colon cancer	0.000685	0.00333	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—TP53—colon cancer	0.000657	0.00319	CbGpPWpGaD
Vidarabine—Dizziness—Methotrexate—colon cancer	0.000647	0.00151	CcSEcCtD
Vidarabine—Vomiting—Methotrexate—colon cancer	0.000622	0.00145	CcSEcCtD
Vidarabine—Rash—Methotrexate—colon cancer	0.000617	0.00144	CcSEcCtD
Vidarabine—Dermatitis—Methotrexate—colon cancer	0.000617	0.00144	CcSEcCtD
Vidarabine—Headache—Methotrexate—colon cancer	0.000613	0.00143	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—BRAF—colon cancer	0.000592	0.00287	CbGpPWpGaD
Vidarabine—Nausea—Methotrexate—colon cancer	0.000581	0.00136	CcSEcCtD
Vidarabine—ADK—Metabolism—ABCB1—colon cancer	0.000574	0.00279	CbGpPWpGaD
Vidarabine—ADK—Metabolism—TYMS—colon cancer	0.000564	0.00274	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—CDKN1A—colon cancer	0.000543	0.00264	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—EP300—colon cancer	0.000527	0.00256	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AXIN2—colon cancer	0.00051	0.00247	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—SRC—colon cancer	0.000502	0.00244	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—NRAS—colon cancer	0.000483	0.00235	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—CTNNB1—colon cancer	0.000445	0.00216	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—CASP3—colon cancer	0.000444	0.00215	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—EGFR—colon cancer	0.00044	0.00214	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—CDKN1A—colon cancer	0.000418	0.00203	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—KRAS—colon cancer	0.000416	0.00202	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PPARG—colon cancer	0.0004	0.00194	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ABCB1—colon cancer	0.00039	0.0019	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—SRC—colon cancer	0.000386	0.00188	CbGpPWpGaD
Vidarabine—ADA—Metabolism—TYMS—colon cancer	0.000383	0.00186	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CA—colon cancer	0.000382	0.00186	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—TP53—colon cancer	0.000377	0.00183	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—NRAS—colon cancer	0.000372	0.0018	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—HRAS—colon cancer	0.000354	0.00172	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—EGFR—colon cancer	0.000339	0.00164	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—KRAS—colon cancer	0.00032	0.00155	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PTGS2—colon cancer	0.000314	0.00153	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—AKT1—colon cancer	0.000312	0.00152	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—PIK3CA—colon cancer	0.000294	0.00143	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—HRAS—colon cancer	0.000272	0.00132	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PPARG—colon cancer	0.000272	0.00132	CbGpPWpGaD
Vidarabine—ADK—Metabolism—EP300—colon cancer	0.000261	0.00127	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—AKT1—colon cancer	0.00024	0.00117	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PTGS2—colon cancer	0.000214	0.00104	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PIK3CA—colon cancer	0.000193	0.000939	CbGpPWpGaD
Vidarabine—ADA—Metabolism—EP300—colon cancer	0.000178	0.000863	CbGpPWpGaD
Vidarabine—ADK—Metabolism—AKT1—colon cancer	0.000158	0.000767	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FGFR3—colon cancer	0.000147	0.000715	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—APC—colon cancer	0.000135	0.000656	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—NRAS—colon cancer	0.000135	0.000656	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PIK3CA—colon cancer	0.000131	0.000638	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—BRAF—colon cancer	0.000127	0.000617	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—EGFR—colon cancer	0.000123	0.000598	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PIK3CA—colon cancer	0.000118	0.000571	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—KRAS—colon cancer	0.000116	0.000565	CbGpPWpGaD
Vidarabine—ADA—Metabolism—AKT1—colon cancer	0.000107	0.000521	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PIK3CA—colon cancer	0.000107	0.000519	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—HRAS—colon cancer	9.89e-05	0.00048	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—AKT1—colon cancer	9.61e-05	0.000467	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CASP3—colon cancer	9.53e-05	0.000462	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CCND1—colon cancer	9.27e-05	0.00045	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CTNNB1—colon cancer	9.18e-05	0.000446	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CDKN1A—colon cancer	8.97e-05	0.000435	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—AKT1—colon cancer	8.73e-05	0.000424	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—EP300—colon cancer	8.54e-05	0.000414	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SRC—colon cancer	8.3e-05	0.000403	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—VEGFA—colon cancer	8.08e-05	0.000392	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NRAS—colon cancer	7.98e-05	0.000388	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MYC—colon cancer	7.44e-05	0.000361	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TGFB1—colon cancer	7.42e-05	0.00036	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—EGFR—colon cancer	7.27e-05	0.000353	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—KRAS—colon cancer	6.87e-05	0.000334	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PIK3CA—colon cancer	6.31e-05	0.000306	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TP53—colon cancer	6.11e-05	0.000296	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HRAS—colon cancer	5.84e-05	0.000284	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AKT1—colon cancer	5.16e-05	0.00025	CbGpPWpGaD
